<DOC>
	<DOCNO>NCT01472367</DOCNO>
	<brief_summary>The purpose study assess safety addition sitagliptin , effect hemoglobin A1c ( A1C ) , fast plasma glucose ( FPG ) proportion patient require glycemic rescue therapy pediatric patient 10-17 year age ( inclusive ) type 2 diabetes mellitus ( T2DM ) inadequate glycemic control metformin therapy ( alone combination insulin ) . The primary hypothesis addition sitagliptin reduces A1C addition placebo 20 week treatment . Participants complete 20-week base period study may choose participate extension period study continue treatment assigned base period additional 34 week .</brief_summary>
	<brief_title>A Study Safety Efficacy MK-0431A Pediatric Participants With Type 2 Diabetes Mellitus ( MK-0431A-170 )</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Has Type 2 Diabetes Mellitus ( T2DM ) Is metformin monotherapy ( ≥1500 mg/day ) ≥12 week A1C ≥6.5 % ≤10.0 % OR stable dos metformin ( ≥1500 mg/day ) insulin ≥12 week A1C ≥7.0 % ≤10 % . NOTE : Participants daily dose metformin great equal 1000 mg/day , less 1500 mg/day may eligible documentation high dos tolerate . Between 10 17 year age day sign informed consent randomization occur prior 18th birthday . Participant family member adult closely involved daily activity participate participant 's treatment study protocol ( i.e. , available telephone call , study visit administration study medication need ) . Known type 1 diabetes mellitus document evidence positive diabetes autoantibody ( perform participant diagnose diabetes ) . Known monogenic diabetes , secondary diabetes , genetic syndrome disorder know affect glucose tolerance diabetes . Symptomatic hyperglycemia and/or moderate large ketonuria require immediate initiation another antihyperglycemic agent . Participant previously take dipeptidyl peptidaseIV ( DPP4 ) inhibitor ( sitagliptin , vildagliptin , alogliptin , saxagliptin ) glucagonlike peptide1 ( GLP1 ) receptor agonist ( exenatide liraglutide ) . Exhibits abnormal growth pattern treat growth hormone . History idiopathic acute pancreatitis chronic pancreatitis .</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>